Eylea

FDA Approves Eylea to Treat Diabetic Retinopathy and DME

Breakthrough therapy designation granted to Eylea for the treatment of Diabetic Retinopathy with Diabetic Macular Edema. Eylea is administered by a physician once a month for the first five treatments and then once every two months.